25 May 2013
Keywords: Canada, Drug review process, Cancer drugs, Cost-effectiveness, pCODR
Article | 14 July 2011
Cancer patients and clinicians in Canadians are set to benefit from the implementation of the pan-Canadian Oncology Drug Review (pCODR), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 July 2011
13 July 2011
24 May 2013
© 2013 thepharmaletter.com